Advair® HFA
COMBINATIONS (DUO)
INHALED CORTICOSTEROID + LONG-ACTING BETA-2 AGONIST (ICS + LABA)
Class
Inhaled corticosteroid (ICS)
Long-acting beta-2 agonist (LABA)
Active ingredient
Fluticasone propionate
Salmeterol (as the xinafoate salt)
Device
- Metered-dose inhaler
Age
- 12 +
Typical use
Asthma
uncontrolled on low dose ICS
COPD (off-label)
in addition to a LAMA, when exacerbating on dual bronchodilation (LAMA/LABA)
Marketed strength
- 125/25 mcg
- 250/25 mcg
Number of doses
- 120 doses
Dose indicator
- Yes | Numerical
Usual adult dosage
Low | 125/25 mcg – 1 inh BID
Medium | 250/25 mcg – 2 inh BID
High | 500/25 mcg – 2 inh BID
Usual pediatric dosage
3-11 years
Low | 125/25 mcg – 1 inh QD
Medium | 125/25 mcg – 1 inh BID12-17 years
See adult dosage
Required inspiratory flow
< 30 L/min
Zero internal resistance (R0)
Public coverage
MN | Open/Regular Benefit
All provinces except MN | Restricted Benefit with criteria
Advantages
- Suitable for low inspiratory flows
- No synchronism required with a spacer
Disadvantages
- BID dosing
- Cumbersome with a spacer
- Contain greenhouse gases
- Expensive
Product monograph
Download